Company Targets OTCQB and NASDAQ Uplisting With Breakthroughs in Drug Repurposing, Functional Medicine, and Strategic AcquisitionsSEATTLE, July 08, 2025 (GLOBE…
CAMBRIDGE, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to…
Expands use of the Certara Pinnacle 21® (P21) enterprise software platform to optimize clinical data flows for speed and qualityRADNOR,…
MIAMI and JERUSALEM, July 08, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (“OPKO”) and Entera Bio Ltd. (NASDAQ:…
Combined company will leverage services and technology platforms to offer a broad portfolio of integrated solutions to pharmaceutical and device…
MIAMI and JERUSALEM, July 08, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (“OPKO”) and Entera Bio Ltd. (NASDAQ:…
Drug-drug interaction (“DDI”) clinical studies help identify the potential for side effects, or in some cases, reduced therapeutic efficacy, that…
ApoCII amyloidosis, resulting from abnormal organ deposition of toxic fibrillar amyloid proteins, is an ultra-rare condition that mostly affects the…
Substantial clinical need expected to facilitate rapid overall trial enrollmentHOUSTON, July 08, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:…
Dosing of the first patient in Phase 2b marks an important transition of the RESOLVE trial from a Phase 2a…